Business Context and Reporting Period
This Form 8-K Current Report was filed by IOVANCE BIOTHERAPEUTICS, INC. on June 12, 2020, regarding events occurring on June 10, 2020. The filing addresses a change in the Company's senior financial leadership.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of CFO: Timothy Morris ceased serving as Chief Financial Officer effective June 10, 2020.
- Appointment of Interim CFO: Michael C. Swartzburg, previously the Company's Vice President, Finance since March 2018, was appointed as interim Principal Financial Officer and Principal Accounting Officer effective June 10, 2020.
- Background: Mr. Swartzburg brings prior experience from Adverum Biotechnologies, One Medical Group, and MAP Pharmaceuticals, and began his career at Ernst & Young.
Guidance, Outlook, and Risks
Management stated that the Company expects no impact to its past and future financial reporting as a result of this leadership change. The filing confirms there are no arrangements or understandings between Mr. Swartzburg and other persons regarding his appointment, nor are there family relationships with directors or officers requiring disclosure.
Investor Verification Checklist
- Verify the effective date of Timothy Morris's departure (June 10, 2020).
- Confirm Michael C. Swartzburg's new title as interim Principal Financial Officer and Principal Accounting Officer.
- Review Mr. Swartzburg's tenure as Vice President, Finance starting in March 2018.
- Note the Company's assertion that financial reporting continuity is maintained.